Keyword: Olivier Brandicourt
Sanofi's Q3 results are feeding fears that its innovation engine may not be able to outpace the decline in its aging diabetes unit.
Sanofi’s loss is Almirall’s gain. In its second diabetes exec shift since last May, EVP Peter Guenter jumped to the top job at derm-focused Almirall.
FiercePharma kept track as the industry launched drugs, made deals, lost patents, shrank, grew, innovated and revolutionized since 2007. Here's how.
Six senators are railing on Sanofi for its role in a Zika pricing dustup that’s gained considerable attention since last year.
Sanofi Chairman Serge Weinberg says the French drug giant doesn’t need any new purchases.
Sanofi may be late to the pricing-pledge party, but it’s not stopping with 9.9% price-hike limits. Instead, it's promising to keep any price increases at or below a health inflation index projected at 5.4% in 2017.
Sanofi CEO Olivier Brandicourt has been criticized for failing to pull off a couple of big acquisitions, but his more mundane deal to get Boehringer Ingelheim’s consumer health business helped it turn in a surprisingly strong Q1.
As Sanofi's Genzyme unit gears up for a blockbuster Dupixent launch, CEO David Meeker is making an exit, with insider Bill Sibold taking his place.